Étiquette : trouble mental

Reefer Madness : A Case of Cannabis-Induced Psychosis, Matthew C. Ballenberger et al., 2019

Reefer Madness : A Case of Cannabis-Induced Psychosis Matthew C. Ballenberger,  Robert D. Glatter,  Daniel P. Klein,  Steven Mandel, Medscape Psychiatry,  August 15, 2019 Clinical Presentation A 32-year-old woman with a history of iron-deficiency anemia was brought in by ambulance because of altered mental status. The patient's sister and boyfriend reported that 1 day before presentation, the patient had ingested a marijuana edible and a few hours later developed fatigue and nausea, followed by at least 15 episodes of nonbloody, nonbilious, projectile vomiting throughout the night. In the morning, she became very pale, her lips turned blue, and she became stiff, losing consciousness for [...]

Lire la suite

Lysergic Acid Diethylamide and Psilocybin Revisited, Mark A. Geyer, 2015

Lysergic Acid Diethylamide and Psilocybin Revisited Mark A. Geyer Biological Psychiatry, 2015, Volume 78, Issue 8, 544-553 https://doi.org/10.1016/j.biopsych.2015.08.003   The past decade brought the beginnings of a renaissance in research on psychedelic drugs. Two articles in this issue of Biological Psychiatry signify that the resurrection of this long ignored topic has begun to mature and bear at least the promise of fruit. In the early 1970s, the onset of the “War on Drugs” brought with it a near-total hiatus in serious research on psychedelic drugs, especially in the United States. The resumption of credible work in this area has come from Switzerland, where many of [...]

Lire la suite

Model Psychoses Induced by LSD-25 in Normals. I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction, Nicolas A. Bercelet al., 1956

Model Psychoses Induced by LSD-25 in Normals. I. Psychophysiological Investigations, with Special Reference to the Mechanism of the Paranoid Reaction Nicolas A. Bercel, Lee E. Travis, Leonard B. Olinger & E. Dreikurs AMA Archives of Neurology and Psychiatry, 1956, 588-611 republishing :Psychopathology: A Source Book (pp. 605–639). DOI: https://doi.org/10.4159/harvard.9780674367012 Keywords : Cardiovascular Agents, Ergot Alkaloids, adverse effects, Lysergic Acid Diethylamide, Mental Disorders, Oxytocics, Paranoid Disorders, Psychotic Disorders INTRODUCTION Experimental psychosis has a long history. It might have started with the administration of Cannabis indica boiling in wine to the ancient Hun warriors, resulting in mental obfuscation, as they were prepared for surgery because of wounds sustained in battle. [...]

Lire la suite

Hallucinogen persisting perception disorder after psilocybin consumption : a case study, Marie-Laure Espiard et al., 2005

Hallucinogen persisting perception disorder after psilocybin consumption : a case study Marie-Laure Espiard, Laurent Lecardeur, Pascale Abadie, Isabelle Halbecq, Sonia Dolfuss European Psychiatry, 2005, 20, (5-6), 458-60 DOI: 10.1016/j.eurpsy.2005.04.008   Abstract The recurrence of flashbacks without acute or chronic hallucinogen consumption has been recognized in the DSM IV criteria as the hallucinogen persisting perception disorder (HPPD). Perceptual disturbances may last for 5 years or more and represent a real psychosocial distress. We reported here a case of a 18 year-old young man presenting HPPD after a mixed intoxication with psylocibin and cannabis. This report shows symptomatic recurrences persisting more than 8 months. Various differential diagnoses were [...]

Lire la suite

Survey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences, Theresa M. Carbonaro et al., 2016

Survey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert Jesse, Matthew W. Johnson and Roland R. Griffiths Journal of Psychopharmacology, 2016, 1 –11 DOI: 10.1177/0269881116662634 Abstract Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst “bad trip”) after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging [...]

Lire la suite

Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis, Robin L. Carhart-Harris et al., 2012

Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis Robin L. Carhart-Harris, Robert Leech, David Erritzoe, Tim M. Williams, James M. Stone, John Evans, David J. Sharp, Amanda Feilding, Richard G. Wise, and David J. Nutt Schizophrenia Bulletin, 2012 doi: 10.1093/schbul/sbs117   model of psychosis. This study measured the effects of psilocybin on resting-state network and thalamo-cortical functional connectivity (FC) using functional magnetic resonance imaging (fMRI). Fifteen healthy volunteers received intravenous infusions of psilocybin and placebo in 2 task-free resting-state scans. Primary analyses focused on changes in FC between the default-mode- (DMN) and task-positive network (TPN). Spontaneous activity in the DMN is orthogonal [...]

Lire la suite

From experimental psychosis to resolving traumatic pasts – Psychedelic Research in Communist Czechoslovakia, 1954‑1974, Sarah Marks, 2015

From experimental psychosis to resolving traumatic pasts - Psychedelic Research in Communist Czechoslovakia, 1954‑1974 De la psychose expérimentale à la guérison des traumatismes du passé : la recherche psychédélique en Tchécoslovaquie communiste, 1954‑1974 Sarah Marks Cahiers du monde russe, 2015, 56, 1, 53-75. DOI: 10.4000/monderusse.8165   The mid‑twentieth century saw an abundance of new theories of human behaviour and mental disorder, many of which were inspired by new developments in broader scientific fields, from cybernetics and genetics, to pharmaceuticals and new technologies of psychological testing1. There is a developing historical literature on the development of psychiatry in Western Europe and North America, yet we know little [...]

Lire la suite

Flashback : Psychiatric Experimentation With LSD in Historical Perspective, Erika Dyck, 2005

Flashback : Psychiatric Experimentation With LSD in Historical Perspective Erika Dyck Canadian Journal of Psychiatry, 2005, Vol 50, No 7, 381-388. Doi : 10.1177/070674370505000703   In the popular mind, d-lysergic acid diethylamide (LSD) research in psychiatry has long been associated with the CIA-funded experiments conducted by Ewen Cameron at the Allen Memorial Institute in Montreal, Quebec. Despite this reputation, a host of medical researchers in the post–World War II era explored LSD for its potential therapeutic value. Some of the most widespread trials in the Western world occurred in Saskatchewan, under the direction of psychiatrists Humphry Osmond (in Weyburn) and Abram Hoffer (in Saskatoon). These [...]

Lire la suite

Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Meth-amphetamine in Healthy Volunteers. A Double-Blind, Placebo-Controlled PET Study with [18 F] FDG, Euphrosyne Gouzoulis-Mayfrank et al., 1999

Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Meth-amphetamine in Healthy Volunteers. A Double-Blind, Placebo-Controlled PET Study with [18 F] FDG Euphrosyne Gouzoulis-Mayfrank, Mathias Schreckenberger, Osama Sabri, Christoph Arning, Bernhard Thelen, Manfred Spitzer, Ph.D., Karl-Artur Kovar, Leopold Hermle,  Udalrich Büll, and Henning Sass. NEUROPSYCHOPHARMACOLOGY, 1999–VOL 20, NO 6, 565-581. PII S0893-133X(98)00089-X   The neurometabolic effects of the hallucinogen psilocybin (PSI; 0.2 mg/kg), the entactogen 3,4- methylenedioxyethylamphetamine (MDE; 2 mg/kg) and the stimulant d-methamphetamine (METH; 0.2–0.4 mg/kg) and the drugs’ interactions with a prefrontal activation task were investigated in a double-blind, placebo-controlled human [F-18]fluorodeoxyglucoseFDG-positron emission tomographicPET study (each group: n 5 8). Subjects underwent two scans (control: [...]

Lire la suite

Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems. A Clinical Review, Kevin P. Hill, 2015 ll,

Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems. A Clinical Review Kevin P. Hill JAMA, 2015, 313, (24), 2474-2483. doi:10.1001/jama.2015.6199   This article is based on a conference that took place at theMedicine Grand Rounds at Beth Israel Deaconess Medical Center, Boston, Massachusetts, on May 16, 2014. IMPORTANCE : As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE : To review the pharmacology, indications, and laws related to medical marijuana use. EVIDENCE REVIEW : The medical literature on medical [...]

Lire la suite